A minimal model of tumor growth inhibition

IEEE Transactions on Biomedical Engineering

Volumn 55, Issue 12, 2008, Pages 2683-2690

  Magni, Paolo ^a   Germani, Massimiliano ^b   Nicolao, Giuseppe De ^a   Bianchini, Giulia ^c   Simeoni, Monica ^d   Poggesi, Italo ^e   Rocchetti, Maurizio ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

^c Statistical Analysis System (SAS) Institute Italia   (Italy)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GSK   (Italy)

Author keywords

Anticancer drug discovery; Pharmacodynamics models; Poisson events; Stochastic model; Tumor growth dynamics; Tumor growth model

Indexed keywords

ANTICANCER DRUG DISCOVERY; ANTITUMOR DRUGS; CELLULAR LEVELS; DRUG ACTIONS; DRUG ADMINISTRATIONS; EXPECTED VALUES; LUMPED PARAMETER MODELS; MINIMAL MODELS; PARTIAL DIFFERENTIALS; PLASMA DRUG CONCENTRATIONS; POISSON EVENTS; PRACTICAL USES; PRECLINICAL DEVELOPMENTS; PROLIFERATING CELLS; TUMOR CELLS; TUMOR GROWTH DYNAMICS; TUMOR GROWTH MODEL;

ANIMALS; CELL DEATH; CLUSTER ANALYSIS; DRUG PRODUCTS; DYNAMICS; FUNCTIONS; GROWTH (MATERIALS); MATHEMATICAL MODELS; ORDINARY DIFFERENTIAL EQUATIONS; PHARMACODYNAMICS; POISSON DISTRIBUTION; POISSON EQUATION; PROBABILITY; PROBABILITY DENSITY FUNCTION; PROBABILITY DISTRIBUTIONS; RANDOM PROCESSES; RANDOM VARIABLES; STOCHASTIC CONTROL SYSTEMS; TUMORS;

STOCHASTIC MODELS;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL COUNT; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; POISSON DISTRIBUTION; PROBABILITY; STOCHASTIC PROCESSES; TUMOR BURDEN;

EID: 58149250388     PISSN: 00189294     EISSN: None     Source Type: Journal    
DOI: 10.1109/TBME.2008.913420     Document Type: Article

References (21)

1. G. G. Steel, Growth Kinetics of Tumors. Oxford, U.K.: Clarendon Press, 1977.
2. J. Mattern, M. Bak, E. W. Hahn, and M. Volm, "Human tumor xenografts as model for drug testing," Cancer Metastasis Rev., vol. 7, pp. 263-284, 1988.
3. L. Aarons, M. O. Karlsson, F. Mentre, F. Rombout, J. L. Steimer, and A. van Peer, and COST B15 Experts, "Role of modelling and simulation in phase I drug development," Eur. J. Pharm. Sci., vol. 13, pp. 115-122, 2001.
4. N. L. Komarova, "Mathematical modeling of tumorigenesis: Mission possible," Curr. Opin. Oncol., vol. 17, pp. 39-43, 2005.
5. G. F. Webb, "A cell population model of periodic chemotherapy treatment," in Biomedical Modeling and Simulation. Amsterdam, The Netherlands: Elsevier, 1992, pp. 83-92.
6. L. Cojocaru and Z. Agur, "A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs," Math. Bio., vol. 109, pp. 85-97, 1992.
7. J. C. Panetta and J. A. Adam, "A mathematical model of cycle-specific chemotherapy," Math. Comput. Modell., vol. 22, pp. 67-82, 1995.
8. M. A. J. Chaplain, "Avascular growth, angiogenesis and vascular growth in solid tumors: The mathematical modelling of the stages of tumor development," Math. Comput. Modell., vol. 23, pp. 47-87, 1996.
9. T. L. Jackson and H. M. Byrne, "A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy," Math. Biosci., vol. 164, no. 1, pp. 17-38, 2000.
10. J. Dyson, R. Villella-Bressan, and G. F. Webb, "Asynchronous exponential growth in an age structured population of proliferating and quiescent cells," Math. Biosci., vol. 177-178, pp. 73-83, 2002.
11. I. A. Sidorov, K. S. Hirsch, C. B. Harley, and D. S. Dimitrov, "Cancer treatment by telomerase inhibitors: Predictions by a kinetic model," Math. Biosci., vol. 181, pp. 209-221, 2003.
12. F. Kozusko and Ž. Bajzer, "Gompertzian growth and cell population dynamics," Math. Biosci., vol. 185, pp. 153-167, 2003.
13. L. Spinelli, A. Torricelli, P. Ubezio, and B. Basse, "Modelling the balance between quiescence and cell death in normal and tumor populations," Math. Biosci., vol. 202, pp. 349-370, 2006.
14. R. Wasserman, R. Acharya, C. Sibata, and K. H. Shin, "A patient-specific in vivo tumor model," Math. Biosci., vol. 136, pp. 111-140, 1996.
15. A. Qi, X. Zheng, C. Du, and B. An, "A cellular automaton model of cancerous growth," J. Theor. Biol., vol. 161, pp. 1-12, 1993.
16. R. Chignola, D. Liberati, E. Chiesa, C. Anselmi, R. Foroni, S. Sartoris, A. B. G. Tridente, and G. Andrichetto, "A non-parametric method for the analysis of experimental tumor growth data," Med. Bio. Eng. Comput., vol. 37, pp. 537-542, 1999.
17. M. Simeoni, P. Magni, C. Cammia, G. De Nicolao, V. Croci, E. Pesenti, M. Germani, I. Poggesi, and M. Rocchetti, "Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administrations of anticancer agents," Cancer Res., vol. 64, pp. 1094-1101, 2004.
18. P. Magni, M. Simeoni, I. Poggesi, M. Rocchetti, and G. De Nicolao, "A mathematical model to study the effects of drugs administration on tumor growth dynamics," Math. Biosci., vol. 2, pp. 127-151, 2006.
19. A. Papoulis, Probability, Random Variables and Stochastic Processes.. New York: McGraw-Hill, 1991.
20. D. A. Cameron, W. M. Gregory, A. Bowman, E. D. C. Anderson, P. Levack, P. Forouhi, and R. F. C. Leonard, "Identification of long-term survivors in primary breast cancer by dynamic modeling of tumor response," Br. J. Cancer, vol. 83, pp. 98-103, 2000.
21. L. A. Hammond, S. G. Hilsenbeck, S. G. Eckhardt, J. Marty, G. Mangold, J. R. MacDonald, E. K. Rowinsky, D. D. Von Hoff, and S. Weitman, "Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model," Eur. J. Cancer, vol. 36, pp. 2430-2436, 2000.